Drug Delivery System
IPMD is collaborating with Veteran Administration Greater Los Angeles Healthcare System, and scientists from UCLA School of Medicine, UCLA Department of Chemistry, and UCLA Bio-Engineering to co-develop Aptamer based Drug Delivery System to Non Small Cell Lung Cancer.
Lung cancer is the leading cause of malignancy related mortality with over one million cases reported annually. NSCLC represents 80-85% of all lung cancers. Due to late detection of lung cancer, chemotherapy is the main choice of treatment for lung cancer, however conventional drug treatment has reached a plateau and the survival rate has not improved over the years. Thus new strategies for drug delivery to NSCLC are needed. In this proposal we plan to identify first the aptamers that can specifically bind to NSCLC. Aptamers are single stranded DNA or RNA oligonucleotides that fold into specific 3D structures, and bind to target molecules with high specificity and affinity. Next, we plan to use the NSCLC-specific aptamer for efficient drug delivery.
The completion of the Phase 1 study will help in identification and characterization of aptamer(s) specific for binding to NSCLC and their ability to deliver chemotherapy drugs to cancer cells. The goal of this study is to increase efficiency of chemotherapeutic drugs against lung cancer by targeted drug delivery to cancer cells and decrease the concentration of drug usage to minimize chemotherapy induced side effects. Overall this study will improve the life of cancer patients by improving chemotherapeutic drug delivery in lung cancer.